Tri-Med – proud partner for CHRO-2024
Released on : Oct. 10, 2024
Tri-Med was delighted to be ‘Gold Partner’ for the 22nd International Workshop on Campylobacter, Helicobacter and Related Organisms (CHRO 24), held in Perth, Western Australia, from 7 to 9 October 2024.
CHRO 24 was especially meaningful as the conference represented the 40 year anniversary since Tri-Med founder, Professor Barry Marshall, presented his first publication on Helicobacter pylori (Prof Robin Warren and Prof Barry Marshall Lancet Letters 1983).
Commenting during the conference, Tri-Med Director, Aiden Blechynden said that the paper was the start of a remarkable journey.
“To prove his hypothesis, Professor Marshall needed a simple, non-invasive and accurate means of detecting H. pylori – leading to the invention of PYtest®.
“In turn, Tri-Med was founded in 1996 and PYtest has evolved into one of the world’s most trusted diagnostics for the detection of H. pylori.”
The objective of CHRO2024 was bringing together professionals from various backgrounds to engage in presentations and discussions; exchanging scientific findings and advances related to Campylobacter, Helicobacter and related organisms.
But just as importantly, the conference sought to create a greater link between theory and its ‘real-world’ application.
“We’d like to think that Tri-Med and PYtest is precisely the sort of practical application that can arise from targeted science and innovation such as that considered during CHRO2024.”
“Since 1996, Tri-Med has expanded both its product base and international footprint and now markets PYtest, CLOtest, scintillation and collection fluids and associated therapeutics throughout Australia and to a worldwide market including over 30 export destinations.”
“We’ve recently opened representative offices in India and the United States… part of our ongoing commitment to the detection and treatment of H. pylori, globally,” Mr Blechynden said.